Conclusion
With the data that is available in the published literature shows no
increased risk with biologics over disease matched cohorts with respect
to congenital malformations, preterm delivery, neonatal infection, small
for gestational age, low birth weight, miscarriage and pre-eclampsia.
There is a suggestion of an increased risk of maternal infections in the
treated group but this is likely due to the lack of studies examining
this outcome.
With over 11172 pregnancies exposed to biologics, our study shows these
medications are predominantly safe for the fetus and the mother. More
evidence is required to prove the likely protective effects of these
medications from unwanted outcomes that disease flare may cause in CID
affected pregnancies. This is important for gastroenterologists,
rheumatologists and obstetricians alike when reassuring women regarding
continuation of treatment throughout pregnancy and for refractory
disease during childbearing years.